Predictive value of pAKT/PTEN expression in oral squamous cell carcinoma treated with cetuximab-based chemotherapy

Kalyankrishna, 2006, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol, 24, 2666, 10.1200/JCO.2005.04.8306 Rabinowits, 2012, Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature, Oral Oncol, 48, 1085, 10.1016/j.oraloncology.2012.06.016 Ang, 2002, Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma, Cancer Res, 62, 7350 Boeckx, 2013, Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance, Oncologist, 18, 850, 10.1634/theoncologist.2013-0013 Yokota, 2014, Is biomarker research advancing in the era of personalized medicine for head and neck cancer?, Int J Clin Oncol, 19, 211, 10.1007/s10147-013-0660-4 Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 66, 3992, 10.1158/0008-5472.CAN-06-0191 Di Fiore, 2007, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy, Br J Cancer, 96, 1166, 10.1038/sj.bjc.6603685 Broek, 2015, The PI3 K/Akt/mTOR axis in head and neck cancer: functions, aberrations, crosstalk, and therapies, Oral Dis, 21, 815, 10.1111/odi.12206 Stransky, 2011, The mutational landscape of head and neck squamous cell carcinoma, Science, 333, 1157, 10.1126/science.1208130 Squarize, 2002, Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system, J Oral Pathol Med, 31, 379, 10.1034/j.1600-0714.2002.00142.x Yonemori, 2009, Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy, Med Oncol, 26, 344, 10.1007/s12032-008-9127-2 Mriouah, 2010, Cellular response to cetuximab in PTEN-silenced head and neck squamous cell carcinoma cell line, Int J Oncol, 37, 1555 Scartozzi, 2012, Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab, J Translation Med, 10, 71, 10.1186/1479-5876-10-71 Villaflor, 2005, EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts), Lung Cancer, 49, 10.1016/S0169-5002(05)80244-2 Yonesaka, 2011, Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab, Sci Transl Med, 3, 99ra86, 10.1126/scitranslmed.3002442 van der Veeken, 2009, Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy, Curr Cancer Drug targets, 9, 748, 10.2174/156800909789271495 Sierra, 2011, c-MET as a potential therapeutic target and biomarker in cancer, Ther Adv Med Oncol, 3, S21, 10.1177/1758834011422557 Huang, 2013, Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy, World J Surg Oncol, 11, 307, 10.1186/1477-7819-11-307